Table 2.
Demographic and clinical characteristics of the study cohort.
| Characteristic | Brain surgery | No brain surgery |
|---|---|---|
| (n = 276) | (n = 500) | |
| Age (year) | ||
| ≤ 75 | 267 (96.74%) | 444 (88.8%) |
| >75 | 9 (3.26%) | 56 (11.2%) |
| Sex | ||
| Male | 144 (52.17%) | 250 (50%) |
| Female | 132 (47.83%) | 250 (50%) |
| Race | ||
| White | 237 (85.87%) | 425 (85%) |
| Black | 30 (10.87%) | 50 (10%) |
| Other | 9 (3.26%) | 25 (5%) |
| Income (USD) | ||
| < $38,000 | 42 (15.22%) | 103 (20.6%) |
| $38,000–$62,999 | 147 (53.26%) | 257 (51.4%) |
| ≥$63,000 | 84 (30.43%) | 136 (27.2%) |
| Unknown | 3 (1.09%) | 4 (0.8%) |
| Insurance type | ||
| None | 15 (5.43%) | 21 (4.2%) |
| Private | 129 (46.74%) | 195 (39%) |
| Public | 130 (47.1%) | 278 (55.6%) |
| Unknown | 2 (0.73%) | 6 (1.2%) |
| Facility volume (cases/year) | ||
| ≤ 45 | 151 (54.7%) | 263 (52.6) |
| >45 | 125 (45.3%) | 237 (47.4%) |
| Charlson-Deyo score | ||
| 0 | 184 (66.66%) | 311 (62.2%) |
| 1 | 72 (26.09%) | 119 (23.8%) |
| 2 | 20 (7.25%) | 70 (14%) |
| Chemotherapy | ||
| Yes | 189 (68.48%) | 263 (52.60%) |
| No | 87 (31.52%) | 237 (47.40%) |
| Type of surgical resection | ||
| Sublobar resection | 43 (15.58%) | 174 (34.8%) |
| Lobectomy or larger resection | 214 (77.54%) | 290 (58%) |
| Unknown | 19 (6.88%) | 36 (7.2%) |
| Pathologic T stage | ||
| T1 | 79 (28.62%) | 116 (23.2%) |
| T2 | 112 (40.58%) | 173 (34.6%) |
| T3 | 37 (13.41%) | 75 (15%) |
| T4 | 12 (4.35%) | 24 (4.8%) |
| Unknown | 36 (13.04%) | 112 (22.4%) |
| Pathologic N stage | ||
| N0 | 154 (55.8%) | 189 (37.8%) |
| N1 | 40 (14.49%) | 68 (13.6%) |
| N2 | 31 (11.23%) | 72 (14.4%) |
| N3 | 0 (0%) | 5 (1%) |
| Unknown | 51 (18.48%) | 166 (33.2%) |